Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Cancer 3, 945–951 (1 December 2003) | doi:10.1038/nrc1234
Searching for the elusive targets of farnesyltransferase inhibitors
&
Abstract
Farnesyltransferase (FTase) inhibitors (FTIs) were developed originally as anti-RAS compounds and novel target-based drugs for cancer treatment. The analyses of FTIs continue in the clinic, but the antitumour activity cannot be ascribed simply to inhibition of RAS. Although FTI action is due to inhibition of FTase, and RAS proteins are indeed substrates for this enzyme, the RAS proteins that are most frequently mutated in human cancers escape FTI inhibition. RHOB has been suggested as a target, but is this issue resolved or do the crucial targets of FTIs remain to be identified?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
